Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Documenti analoghi

• Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
  di: Egle, Alexander, et al.
  Pubblicazione: (2018)
• Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial
  di: Egle, Alexander, et al.
  Pubblicazione: (2019)
• A Phase I Study of Lenalidomide in Combination with Fludarabine and Rituximab in Previously Untreated CLL/SLL
  di: Brown, Jennifer R, et al.
  Pubblicazione: (2010)
• Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia
  di: Gassner, Franz J., et al.
  Pubblicazione: (2014)
• Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
  di: Badoux, Xavier C., et al.
  Pubblicazione: (2011)